LB Pharmaceuticals Inc Common Stock
LB Pharmaceuticals Inc Common Stock (LBRX) Revenue
Annual & quarterly revenue history · segment & region breakdown
LBRX · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsLB Pharmaceuticals Inc Common Stock trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2022 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | — |
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income LB Pharmaceuticals Inc Common Stock receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
LB Pharmaceuticals Inc Common Stock reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from LB Pharmaceuticals Inc Common Stock's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
LBRX revenue · 4 questionsLBRX's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · LB Pharmaceuticals Inc Common Stock SEC filings · GAAP · LB Pharmaceuticals Inc Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026